Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Monotherapy in Highly Active NMOSD
NCT03062579Phase 2Completed
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD). Started Feb 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT03062579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062579.